Thus, IL-2 has the potential to activate tumor-reactive T effector and memory cells and NK cells to induce antitumor immunity, but also Tregs that may limit inflammation, self-reactivity, and anti-tumor responses. The gene discussed is IL2; the disease is neoplasm.